NovaSight

NovaSight is medical device company with a mission to prevent vision impairments among pediatric patients using eye tracking based technology in novel diagnostic, therapeutic and preventive solutions, especially designed for the unique needs of children. NovaSight focuses on three major verticals: vision treatment, vision diagnostics and prevention and monitoring of visual health conditions. Available in the US and Italy, the CureSight™ is an FDA cleared and CE marked amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp - and providing the amblyopic eye with a normal, high contrast, image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together. In addition, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The EyeSwiftPRO tests are grouped into automated ‘protocols’ such as amblyopia monitoring, binocular vision, etc. with each protocol running the unitary tests that are of clinical relevance to the protocol. At the end of each protocol, a clear report which is easily understood by the operator and the patient is created. NovaSight is also in the process of developing TrackSight™, a software as a service (SaaS) solution for myopia prevention and visual health monitoring. TrackSight is designed for use by children on laptops and tablets for both educational and leisure purposes as well as adults at the workplace for objective eye fatigue and dry eye monitoring.

NovaSight has raised $30.97M in total funding across 6 rounds. The company is currently at the A stage. Key investors include Sanara Capital, Infinity China, Rimonci Capital.

NovaSight was founded in 2016 by Danny Oz (Founder & CTO).

NovaSight operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Semiconductors & Electronics, Wearables, Platforms & Interfaces, Software, Data Storage, Cloud, Artificial Intelligence, Deep Learning, Computer Vision. Target customers: Consumers, Demographics & Family, Children, Healthcare & Life Sciences, Healthcare, Providers.

NovaSight is based in Lod, Israel, Center District. The company also has offices abroad.